The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to systematically evaluate the effect of DMDs on disability progression in RRMS.We perform...
Main Authors: | Georgios Tsivgoulis, Aristeidis H Katsanos, Nikolaos Grigoriadis, Georgios M Hadjigeorgiou, Ioannis Heliopoulos, Panagiotis Papathanasopoulos, Constantinos Kilidireas, Konstantinos Voumvourakis, Efthimios Dardiotis, HELANI (Hellenic Academy of Neuroimmunology) |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4671570?pdf=render |
Similar Items
-
The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
by: Georgios Tsivgoulis, et al.
Published: (2016-01-01) -
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
by: Georgios Tsivgoulis, et al.
Published: (2015-01-01) -
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis
by: Georgios Tsivgoulis, et al.
Published: (2015-09-01) -
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
by: Georgios Efthymiou, et al.
Published: (2017-08-01) -
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
by: Aigli G. Vakrakou, et al.
Published: (2023-07-01)